Form 8-K SALIX PHARMACEUTICALS For: Aug 07
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/2/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- DataMeds AI's Corexa Pharmacy tops $1M in monthly revenue
- Equities rebound to close higher as surging Treasury yields recede
- onsemi cuts Synaptics deal price to $5.7B after rival bid
- Wells Fargo names 13 stocks as overweight tactical ideas
- Twilio, Vylor set to join S&P 500 as index reshuffles members
Salix Pharma (SLXP), Progenics (PGNX) Receive User Fee Goal Date for Relistor sNDA
August 11, 2014 7:01 AM EDTSalix Pharma (Nasdaq: SLXP) and Progenics Pharmaceuticals (Nasdaq: PGNX) announced that the Food and Drug Administration (FDA or Agency) has informed Salix that the supplemental New Drug Application (sNDA) for RELISTOR (methylnaltrexone bromide) Subcutaneous Injection, 20 mg/ml, for the treatment of opioid-induced constipation (OIC) in patients taking opioids for chronic non-cancer pain has been assigned a user fee goal date of September 29, 2014.
On... More
Salix Pharmaceuticals Ltd (SLXP) Misses Q2 EPS by 10c
August 7, 2014 4:45 PM EDTSalix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q2 EPS of $1.59, $0.10 worse than the analyst estimate of $1.69. Revenue for the quarter came in at $382 million versus the consensus estimate of $397.06 million.
For earnings history and earnings-related data on Salix Pharmaceuticals Ltd (SLXP) click here.
... More